Global Gene Therapy Market Report 2022: Amid the COVID-19 Crisis, the Market is Projected to Reach a Revised Size of $2.7 Billion by 2026

·6 min read
Company Logo
Company Logo

Dublin, Aug. 19, 2022 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to's offering.

Global Gene Therapy Market to Reach $2.7 Billion by 2026

Amid the COVID-19 crisis, the global market for Gene Therapy estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$2.7 Billion by 2026, growing at a CAGR of 19.5% over the analysis period.

Gene therapy is growing at an impressive pace, having emerged as a prospective segment in the field of biotechnology, and also presenting a bright outlook, given the increasing investments in R&D as well as mounting incidence of genetic disorders.

The rapid growth in global population, along with growing incidence of cancer and chronic disorders, introduction of novel gene therapy-based products, strong clinical evidence for therapeutic efficacy and safety of gene therapy products, favorable reimbursement policies and guidelines, and rapidly growing demand for chimeric antigen receptor (CAR) T-cell-based gene therapies are some of the key factors driving growth in the market.

Moreover, rising awareness regarding the potential of gene therapy in treating various chronic diseases, ethical acceptability of gene therapy for treating cancer, and increased government support for promoting research in gene therapy are expected to bolster the market growth in the coming years

Viral, one of the segments analyzed in the report, is projected to record 19.7% CAGR and reach US$3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Viral segment is readjusted to a revised 17.6% CAGR for the next 7-year period. Viral segment accounts for a major share of the market.

Deployment of viral vectors in delivery of gene therapy drugs continue to exhibit progressive tide, driven by wider availability of advanced mechanisms for quicker and effective modifications of viruses such as Adeno-Associated Virus (AAV), Lentivirus, Retrovirus & Gamma-Retrovirus, Herpes Simplex Virus, Poxvirus, and Vaccinia Virus, among others.

Robust improvement in RNA, DNA, and oncolytic viral vectors is encouraging the prospects of viral vectors. Non-viral vectors are perceived as safer substitute to viral vectors, and playing an important role in redirecting pharmaceutical industries and clinicians towards gene therapy. The demand for non-viral vectors is also attributed to factors like easy characterization, mass production, enhanced reproducibility, superior transgenic capacity, and few bio-security issues.

The U.S. Market is Estimated at $628.1 Million in 2022, While China is Forecast to Reach $82.3 Million by 2026

The Gene Therapy market in the U.S. is estimated at US$628.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$82.3 Million by the year 2026 trailing a CAGR of 25.1% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.3% and 18.9% respectively over the analysis period.

Within Europe, Germany is forecast to grow at approximately 18.6% CAGR. The presence of large market players, availability of favorable reimbursement policies, prevalence of advanced healthcare infrastructure, high healthcare spending, the availability of high disposable income among the consumer base, and rising incidence of chronic diseases are some of the key factors that are expected to continue driving growth in the US market.

In Europe, rising funding for cell and gene therapy programs in countries such as the UK is expected to steer the gene therapy market in the region. European companies with commercial gene therapy portfolios are actively seeking roll out of their treatments in other regional markets by winning approvals from concerned regulatory bodies.

Growth in the Asia-Pacific region is attributed to the rising prevalence of cancer, growing government initiatives for improving healthcare infrastructure, and increasing healthcare expenditure by various countries across the region.

What`s New for 2022?

  • Global competitiveness and key competitor percentage market shares

  • Market presence across multiple geographies - Strong/Active/Niche/Trivial

  • Online interactive peer-to-peer collaborative bespoke updates

  • Access to the digital archives

  • Complimentary updates for one year

Key Topics Covered:




  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

  • A Prelude to Gene Therapy

  • Classification of Gene Therapies

  • COVID-19 Causes Gene Therapy Market to Buckle & Collapse

  • COVID-19 Impact on Different Aspects of Gene Therapy

  • Manufacturing & Delivery

  • Research & Clinical Development

  • Commercial Operations & Access

  • Managing Derailed Operations

  • Focus on Clinical Development Programs

  • Targeting Manufacturing & Delivery Strategies

  • Securing Supplies

  • Remote Working

  • Gene Therapy Set to Witness Rapid Growth Post COVID-19

  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

  • By Vector Type


  • Adeno-Associated Virus Vectors

  • Lentivirus


  • US and Europe Dominate the Gene Therapy Market

  • Oncology Represents the Largest Indication for Gene Therapy

  • Market Outlook


2. FOCUS ON SELECT PLAYERS(Total 154 Featured):

  • Abeona Therapeutics Inc.

  • Adaptimmune Therapeutics Plc

  • Advantagene, Inc.

  • Adverum Biotechnologies, Inc

  • Akcea Therapeutics

  • Alnylam Pharmaceuticals, Inc.

  • Amgen Inc

  • Anchiano Therapeutics, Inc.

  • AnGes, Inc.

  • Applied Genetic Technologies Corporation

  • Audentes Therapeutics, Inc.

  • Biogen

  • bluebird bio, Inc.

  • Chiesi Farmaceutici S.p.A

  • CRISPR Therapeutics AG

  • Editas Medicine, Inc.

  • Gilead Sciences, Inc.

  • Intellia Therapeutics, Inc.

  • Jazz Pharmaceuticals, plc.

  • Juno Therapeutics, Inc

  • Merck KGaA

  • MolMed S.p.A.

  • Novartis Gene Therapies

  • Orchard Therapeutics plc


  • Sangamo Therapeutics, Inc.

  • Sarepta Therapeutics, Inc.

  • Sibiono GeneTech Co. Ltd.

  • Spark Therapeutics, Inc.

  • uniQure N.V.

  • Voyager Therapeutics


  • Availability of Novel Therapies Drive Market Growth

  • Select Approved Gene Therapy Products

  • Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy

  • Lentiviral Vectors Witness Increasing Interest

  • Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy

  • Compelling Level of Technology & Innovation to Ignite Gene Therapy

  • Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases

  • Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine

  • M&As Rampant in Gene Therapy Space

  • Emphasis on Formulating Robust Regulatory Framework

  • Strong Gene Therapy Pipeline

  • Gene Therapy: Phase III Clinical Trials

  • OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR

  • Growing Funding for Gene Therapy Research

  • Market Issues & Challenges




For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900